Trial
NCT03397186
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI); Janssen Pharmaceuticals
Condition
Myxoid Liposarcoma
Intervention
Biopsy
Why stopped
Administrative
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-10